Clinical application of the 70-gene profile: the MINDACT trial.
The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.
Cardoso
Fatima
F
Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium.
Van't Veer
Laura
L
Rutgers
Emiel
E
Loi
Sherene
S
Mook
Stella
S
Piccart-Gebhart
Martine J
MJ
D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D003657:Decision Making; D005240:Feasibility Studies; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D054928:Validation Studies as Topic